Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302 Coya